Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, Bramlage P, Schiffer M, Achenbach S, Schmieder R (2021)
Publication Type: Journal article
Publication year: 2021
DOI: 10.1002/ehf2.13622
Aims Impairment of vascular function contributes to the progression of chronic heart failure (HF) by increasing the afterload. Treatment with selective sodium-glucose cotransporter 2 (SGLT2) inhibitors improves the prognosis of HF, but the precise mechanisms remain unclear. The aim of this study was to analyse the effect of empagliflozin on vascular function in patients with HF.
APA:
Kolwelter, J., Bosch, A., Jung, S., Stabel, L., Kannenkeril, D., Ott, C.,... Schmieder, R. (2021). Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure. ESC Heart Failure. https://doi.org/10.1002/ehf2.13622
MLA:
Kolwelter, Julie, et al. "Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure." ESC Heart Failure (2021).
BibTeX: Download